Gryphon Bio is a preclinical-stage therapeutic bioconjugate company created to harness our co-founders’ discovery of unexpected waves of molecules as novel therapeutic targets and temporal biomarkers in the blood to accelerate central nervous system (CNS) repair. We are developing a promising, diversified pipeline of lead therapeutic bioconjugates to accelerate CNS repair by following clues from nature’s sequence of cellular and molecular events. Each compound has a unique mechanism(s) of action (MOA) and pharmacokinetic/pharmacodynamic (PK/PD) profile, compelling biology, and binds to a novel or de-risked therapeutic target(s).
Mission: To develop and market the first therapeutic bioconjugate to accelerate CNS repair.
Vision: To pioneer therapeutic bioconjugates as safe and efficacious CNS medicines to improve the lives of patients.